Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CKD-330 Dose Selection in Essential Hypertension
NCT02206165Phase 2Unknown
- Sponsor
- Chong Kun Dang Holdings
- Start
- Mar 2014
- Primary completion
- Apr 2015
- Modality
- Prodrugs/Conditional Activator Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of candesartan cilexetil, amlodipine in essential hypertension, sponsored by Chong Kun Dang Holdings. Status: unknown.
02
Drugs
candesartan cilexetilamlodipine
03
Conditions
essential hypertension
Beyond the preview
Go deeper on NCT02206165.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02206165.